These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 6284677)

  • 21. A controlled study of cefotetan versus cefotaxime in the treatment of acute infections.
    Schmidt G; Lossnitzer K
    Chemioterapia; 1987 Jun; 6(2 Suppl):371-2. PubMed ID: 3334578
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ambulatory anti-infective therapy. Multicentric studies with cefotaxime treatment of 12,181 patients].
    Pozzi E; Luisetti M; Peona V; Colombo ML
    G Ital Chemioter; 1982; 29(1):21-38. PubMed ID: 6309598
    [No Abstract]   [Full Text] [Related]  

  • 23. [A clinical and laboratory study of China-made cefotaxime].
    Niu WW; Wang QN; Lin YH
    Zhonghua Nei Ke Za Zhi; 1985 Nov; 24(11):641-5, 700. PubMed ID: 3833501
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical study of ceftriaxone (author's transl)].
    Lafaix C; Beucler A; Soussy CJ; Dublanchet A
    Pathol Biol (Paris); 1982 Jun; 30(6):349-52. PubMed ID: 6287387
    [No Abstract]   [Full Text] [Related]  

  • 25. [Ceftriaxone in septic processes].
    Torres A; Aguirre M; Ales JM
    Rev Clin Esp; 1983 Oct; 171(2):103-5. PubMed ID: 6318279
    [No Abstract]   [Full Text] [Related]  

  • 26. Ampicillin/sulbactam compared with cefotaxime in the treatment of lower respiratory tract infections of bacterial etiology.
    Jauregui L; Minns P; Hageage G
    Adv Ther; 1995; 12(1):62-71. PubMed ID: 10150322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cefotiam in infections of granulocytopenic tumor patients].
    Spors S; Seng P; Nossek L
    Med Welt; 1982 Dec; 33(48):1749-50. PubMed ID: 6296600
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical experience with lower doses of cefotaxime in hospitalized patients with serious infections.
    Shah A; Madhavan T; Drelichman V; Price J
    J Chemother; 1989 Jul; 1(4 Suppl):650-1. PubMed ID: 16312575
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical considerations on the use of cefotaxime in infectious complications after resuscitation].
    Mangione S; Giannalia ML
    Minerva Anestesiol; 1983 Nov; 49(11):649-52. PubMed ID: 6322053
    [No Abstract]   [Full Text] [Related]  

  • 30. Carbapenems: monotherapy in intra-abdominal sepsis.
    Wilson SE
    Scand J Infect Dis Suppl; 1995; 96():28-33. PubMed ID: 7652500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical and microbiological study of the use of cefotaxime in a series of predominantly pediatric cases].
    Fabbri A; Marazzi MG; Manno G; Giacchino R
    Minerva Pediatr; 1983 Mar; 35(5):251-6. PubMed ID: 6304483
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical experience of cefotaxime in infections caused by gram-positive pathogens.
    Bassetti D; Solbiati M; Fraizzoli G
    Infection; 1985; 13 Suppl 1():S112-4. PubMed ID: 4055040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefotaxime in the treatment of prophylaxis of surgical infections.
    Wittmann DH; Jones RN; Malledant J; Privitera G
    J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteremia in the 1980s with special reference to the role of cefotaxime.
    Neu HC
    Clin Ther; 1981; 4 Suppl A():55-66. PubMed ID: 6275998
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical experience with the use of a new cephalosporin (cefotaxime) in infectious bronchopulmonary pathology].
    Baldini EV; Bonucchi ME; Lodi SA; Rossi G
    G Ital Chemioter; 1980; 27(2):57-68. PubMed ID: 6281114
    [No Abstract]   [Full Text] [Related]  

  • 36. [Kinetic and clinical studies on a new cephalosporin: Cefotiam].
    Soranzo ML; Capra E; Eandi M; Bosio G; Salassa B; Bendiscioli L; Bramato C; Musso E; Andreoni G; Morelli B; Fabiano A; Di Nola F; Misto P
    Minerva Med; 1982 Oct; 73(39):2671-8. PubMed ID: 6289193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefotaxime: single agent therapy for infections in cancer patients with adequate granulocyte counts.
    Rolston K; Bolivar R; Fainstein V; Jones P; Elting L; Bodey GP
    J Antimicrob Chemother; 1985 Jan; 15(1):91-6. PubMed ID: 3972760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime.
    Toledo C; Salmerón JM; Rimola A; Navasa M; Arroyo V; Llach J; Ginès A; Ginès P; Rodés J
    Hepatology; 1993 Feb; 17(2):251-7. PubMed ID: 8428722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic use of cefotiam in bacterial infections in pediatrics].
    Cerutti F; Gusmano R; Pedrinazzi RC; Ramenghi U; Spada A; Vassena E
    Minerva Pediatr; 1983 Nov; 35(21):1073-8. PubMed ID: 6323941
    [No Abstract]   [Full Text] [Related]  

  • 40. The value of ascitic fluid polymorphonuclear cell count determination during therapy of spontaneous bacterial peritonitis in patients with liver cirrhosis.
    Ljubicic N; Spajic D; Vrkljan MM; Altabas V; Doko M; Zovak M; Gacina P; Mihatov S
    Hepatogastroenterology; 2000; 47(35):1360-3. PubMed ID: 11100352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.